Protocol
B vitamins (folic acid, B6, B12) for brain shrinkage in mild cognitive impairment
In VITACOG, 168 older adults with mild cognitive impairment who took high-dose folic acid, vitamin B6 and vitamin B12 for two years lost brain volume more slowly on MRI (0.76% a year against 1.08%), most clearly in those with high homocysteine An amino acid in the blood that rises when vitamin B12, folate or B6 are low..
Grade C: human trials exist, but they are small, mixed or not yet repeated. This is not a finding that it does not work. How to read a grade →
At a glance
Older adults with mild memory problems took high doses of B vitamins or a dummy pill for two years. On brain scans, the vitamin group lost brain volume more slowly. The effect was largest in people with high homocysteine, a blood marker the vitamins lower. Scans are not the same as memory, and the trial did not show less dementia.
- What was measured
- Brain volume loss on MRI over 2 years.
- How big
- Brain atrophy was 0.76% a year against 1.08% a year with placebo An inactive substitute made to look like the real treatment, so participants cannot tell which one they received..Read from the summary of PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 20838622.
- Who it applies to
- Older adults with mild cognitive impairment.
- Safety
- Serious side effects were no more common than with placebo.
- Compared with
- Placebo.
- Certainty
- Grade C, resting on: One randomized trial with an imaging outcome.
- What would change this grade
- Could rise to B with: Randomized trial of B vitamins. Who: Older adults with mild cognitive impairment and high homocysteine. Measured: Conversion to dementia. Length: At least 3 years.
- Cost
- No price recorded yet.
- Sources
- 1 study cited on this record, listed under Sources.
- For clinicians
- A one-page summary of this record that prints with a clinician's name and practice, folds to a plain-language patient handout, and gives a chart note to paste into the patient record: Printable summary and chart note.
In VITACOG, 168 older adults with mild cognitive impairment who took high-dose folic acid, vitamin B6 and vitamin B12 for two years lost brain volume more slowly on MRI (0.76% a year against 1.08%), most clearly in those with high homocysteine. Brain volume is an imaging measure, not a clinical outcome.
Why this letter
Why this gradeGrade C, small or unreplicated trials. The reasoning, and what the grade does not cover.
Grade C on brain atrophy. One trial found B vitamins slowed brain shrinkage on MRI in mild cognitive impairment (Smith et al., 2010; PMID 20838622).
WHY NOT Bbrain volume on MRI is not an established stand-in for dementia or cognitive decline, and the result has not been replicated The same finding reproduced by a separate research group. A result seen once can be chance or bias; a replicated one is harder to explain away. in a trial of dementia.
WHAT THIS GRADE DOES NOT COVERpeople without high homocysteine or without cognitive impairment, and dementia itself. It also does not cover memory and thinking scores, which were secondary measures and do not carry this letter.
A grade describes the human evidence for a named use. It is not advice, and it is not a judgment on any individual prescription. How the letters are decided →
Who responds: this record's trial reading reports no subgroup that identifies who responds.
Evidence notes: randomized trial
Endpoint The outcome a trial measures to decide whether the treatment worked, such as heart attacks, blood pressure or a symptom score. graded: Rate of brain atrophy on MRI (surrogate)
Last reviewed: November 2026
The trial that would change this grade.
A positive trial of this shape, supported by further trials, would move this entry to B.
Why the current trials fall short
A trial measuring dementia would be needed.
ClinicalTrials.gov, the public registry run by the U.S. National Library of Medicine, lists studies that are recruiting volunteers. The link below searches it for Vitamin B Complex among studies recruiting now. EBL has no relationship with any listed study and receives no payment for this link.
Search recruiting studies of Vitamin B Complex on ClinicalTrials.gov
Dose, form and timing
Homocysteine.
Safety
No safety data. Each caution on this record, sorted by what it rests on.
None recorded.
None recorded.
None recorded.
None recorded.
No safety data: EBL has found no trial or report of harm for this record. That is an absence of evidence, not a finding of safety.
Grade history
How this letter has changedLatest: No. 470 · November 2026 · First graded.
New record in the gap-report batch. In VITACOG, 168 older adults with mild cognitive impairment who took high-dose folic acid, vitamin B6 and vitamin B12 for two years lost brain volume more slowly on MRI (0.76% a year against 1.08%), most clearly in those with high homocysteine. Brain volume is an imaging measure, not a clinical outcome.PMID 20838622
Every change to a letter on this site is dated and published. The full evidence log →
Sources
- Citations
- Every paper cited on this page is matched to its PubMed record on every build.
- Retractions
- None of these papers is retracted or under a journal expression of concern. PubMed is checked again on every build.
- Read against the papers
- November 2026. By a language model (AI-assisted reading), not yet reviewed by a clinician.
- Outside review
- Not yet done. No reviewer outside EBL has checked this record.
What each of these checks can and cannot show: evidence integrity.
The evidence, in fullOne paper, linked to its PubMed record.
Smith et al. (PLoS One, 2010; PMID 20838622): VITACOG, randomized placebo-controlled trial, 168 completers with mild cognitive impairment, folic acid 0.8 mg, vitamin B6 20 mg and vitamin B12 0.5 mg daily for 24 months; brain atrophy 0.76% a year against 1.08%; 53% lower atrophy rate with homocysteine above 13 micromol/L; no difference in serious adverse events.
How EBL searched for the trials (1 search)
The search that was run, what it returned, and what was left out and why, so the absence of evidence can be checked as well as its presence.
("B vitamin*"[tiab] OR "folic acid"[tiab]) AND (atrophy[tiab] OR cognitive[tiab]) AND homocysteine[tiab] AND randomized controlled trial[pt]PubMed watch: does a new study change the grade? (nothing new)
No new paper matching the search behind this grade has been added to PubMed since November 2026.
Last run November 2026. A letter on EBL moves only after a logged review. A new paper never moves a letter by arriving: it is read, the answer is written here, and any change to the letter is published in the evidence log.
For each trial behind a letter on this page, the funding its PubMed record lists. "No funder" means PubMed lists none, not that the trial had no funding.
- Smith et al., 2010, PLoS One (PMID 20838622): PubMed lists funding from Medical Research Council. The PubMed record carries a competing-interest statement.
Disclosure
Educational use only · Not medical advice · EBL grades published human evidence and does not recommend treatment. Stopping a prescription is a decision for your physician.
Evidence Based Longevity, Inc. is owner-operated and edited by Arnold Sandlow, D.C., a California-licensed chiropractor. Evidence Based Longevity publishes in English only · Machine translations are not produced or reviewed by EBL for accuracy
© Evidence Based Longevity, Inc. All rights reserved
These statements have not been evaluated by the Food and Drug Administration. Any grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.
Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →